Hosted on MSN1d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Daily23h
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz1d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
The American Journal of Managed Care5d
Lower Pharmacy Costs Give Ruxolitinib Edge for Patients With MF and Anemia
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
pharmaphorum7d
GSK gets wide FDA approval for myelofibrosis drug
Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...
pharmaphorum9mon
GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis
Omjjara (momelotinib) – which has been predicted by GSK to have blockbuster sales potential – was approved as Ojjaara by the US FDA in September after a three-month delay. It can be used in ...
Hosted on MSN3mon
GSK slips as vaccine outlook is slashed
Specialty medicines performed particularly well, exceeding expectations by 6%, driven by strong sales of Dovato and a launch of Ojjaara, said analysts at Jefferies in a note. General medicines saw ...
Yahoo Finance2d
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...